论文部分内容阅读
目的探讨紫杉醇与顺铂联合化疗治疗宫颈癌的临床疗效。方法选取2015年6月—2016年8月周口市中心医院收治的70例宫颈癌患者,随机分为两组,各35例。对照组采用手术治疗联合术后辅助化疗方式,观察组则于术前采用辅助化疗和手术治疗联合术后化疗方式。对比两组临床疗效、病理情况及并发症发生率。结果对照组患者化疗有效率明显低于观察组,淋巴结阳性率、阴道切缘阳性率、脉管浸润率均高于观察组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论对宫颈癌患者采用紫杉醇与顺铂联合化疗具有较高的安全性,临床效果显著,有助于患者预后的恢复。
Objective To investigate the clinical efficacy of paclitaxel combined with cisplatin in the treatment of cervical cancer. Methods Seventy patients with cervical cancer admitted to Central Hospital of Zhoukou from June 2015 to August 2016 were randomly divided into two groups of 35 cases. The control group received surgical treatment combined with postoperative adjuvant chemotherapy, and the observation group received adjuvant chemotherapy and surgical treatment combined with postoperative chemotherapy before surgery. The clinical efficacy, pathology and complication rates were compared between the two groups. Results The effective rate of chemotherapy in the control group was significantly lower than that in the observation group, the positive rate of lymph node, the positive rate of vaginal margin and the rate of vascular invasion were significantly higher than those in the observation group (P <0.05). The incidence of adverse reactions The difference was not statistically significant (P> 0.05). Conclusions The combination of paclitaxel and cisplatin in patients with cervical cancer has higher safety and clinical effect, which is helpful for the recovery of prognosis.